Oxford Gene Technology appoints Dr David Owen to the Board
Oxford Gene Technology (OGT) announced the appointment of Dr David Owen to the OGT Board as a Non-Executive Director.
After graduating with a PhD in pharmacology, David worked in R&D in the pharmaceutical industry for 20 years (Sandoz and SmithKline and French). He went on to lead technology driven licensing agreements for SmithKline and French as Group Director for Compound and Technology Acquisitions. In 1990 he joined the MRC as CEO of MRC Technology, and led technology transfer activities in patenting, licensing technologies, creating new "start-up" companies and generation of revenues.
In June 2001 David was awarded the OBE for services to medical research and technology transfer.
David is currently Non-Executive Chairman of Abcellute Ltd. and the Cardiff Partnership Fund, Co-Chairman of EMBL Enterprise Management, GmbH, in Heidelberg and is a past President of the Association of European Science and Technology Transfer Professionals.
Other news from the department people
